A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group.

[1]  K. Yoshioka,et al.  Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. , 1995, Journal of hepatology.

[2]  A. Alberti,et al.  Randomized trial comparing three different regimens of alpha‐2a‐interferon in chronic hepatitis C , 1995 .

[3]  P. Marcellin,et al.  Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. , 1995, Gastroenterology.

[4]  J. Alberdi,et al.  Efficacy and safety of α-interferon treatment for chronic hepatitis C in HIV-infected patients , 1995 .

[5]  R. Jover,et al.  [Mortality from chronic liver disease in patients with HIV infection]. , 1995, Medicina clinica.

[6]  C. Sabin,et al.  Morbidity and mortality from transfusion- transmitted disease in haemophilia , 1995, The Lancet.

[7]  O. Weiland,et al.  Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon alone , 1995, Journal of medical virology.

[8]  J. Vicario,et al.  CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. HIV-Hepatitis Spanish Study Group. , 1994, AIDS.

[9]  C. Sabin,et al.  The progression of HCV‐associated liver disease in a cohort of haemophilic patients , 1994, British journal of haematology.

[10]  K. Chayama,et al.  Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.

[11]  P. Simmonds,et al.  Hepatitis C serotype and response to interferon therapy. , 1994, The New England journal of medicine.

[12]  J. Prieto,et al.  Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. , 1993, Gut.

[13]  A. Pesce,et al.  Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients , 1993, The Lancet.

[14]  G. Davis,et al.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.

[15]  L. Stuyver,et al.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. , 1993, The Journal of general virology.

[16]  J. Goedert,et al.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.

[17]  V. Carreño,et al.  Treatment with recombinant α‐interferon of chronic hepatitis C in anti‐HIV‐positive patients , 1993 .

[18]  E. Concia,et al.  Rapid decline of CD4+ cells after IFNα treatment in HIV-1 infection , 1993, The Lancet.

[19]  N. Hayashi,et al.  Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. , 1993, Gastroenterology.

[20]  C. Sabin,et al.  The Progression of HIV disease in a haemophilic cohort followed for 12 years , 1993, British journal of haematology.

[21]  P. Marcellin,et al.  Recombinant Interferon-α for Chronic Hepatitis C in Patients Positive for Antibody to Human Immunodeficiency Virus , 1992 .

[22]  X. Causse,et al.  Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. , 1991, Gastroenterology.

[23]  P. Couzigou,et al.  Recombinant human α‐interferon in patients with chronic non‐A, non‐B hepatitis: A multicenter randomized controlled trial from France , 1991 .

[24]  J. Hoofnagle,et al.  Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. , 1989, Gastroenterology.

[25]  S. Banks,et al.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1989, The New England journal of medicine.

[26]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[27]  J. Hoofnagle,et al.  Therapy of Hepatitis C , 1995, Seminars in liver disease.

[28]  V. Soriano,et al.  High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. , 1994, The Journal of infection.

[29]  L. Serfaty,et al.  Factors predictive of the response to interferon in patients with chronic hepatitis C. , 1994, Journal of hepatology.

[30]  G. Davis.  Prediction of response to interferon treatment of chronic hepatitis C. , 1994, Journal of hepatology.

[31]  V. Carreño,et al.  An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. , 1993, Journal of hepatology.